Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02288715

Enrollment

110

Registered

2014-11-11

Start date

2014-05-31

Completion date

2017-03-31

Last updated

2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

cerebral perfusion pressure, septic encephalopathy

Brief summary

The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.

Detailed description

Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.

Interventions

OTHERno interventions

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* clinical symptoms of sepsis, severe sepsis and septic shock * age over 18 years

Exclusion criteria

* preexisting Neurological diseases * traumatic brain injury * intracranial infectious disease * severe hepatic or renal dysfunction * ICU discharge Within 72 hours * pregnancy

Design outcomes

Primary

Measure	Time frame	Description
relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy	cerebral perfusion pressure is assessed up to 72 hours	To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).

Secondary

Measure	Time frame	Description
Time of ICU stay	All the participants will be followed up until discharge or death, assessed up to 24 months	—
Time of hospital stay	All the participants will be followed up until discharge or death, assessed up to 24 months	—
90-day mortality rate	All the participants will be followed up until 90 days after their enrollment or death	—
Duration of mechanical ventilation	All the participants will be followed up until discharge or death, assessed up to 24 months	—
2-year mortality rate	All the participants will be followed up until 2 years after their enrollment or death	—
1-year quality of life of survivors	All the participants will be followed up until 1 year after their enrollment or death	EQ-5D will be used to evaluate quality of life of survivors
2-year quality of life of survivors	All the participants will be followed up until 2 year after their enrollment or death	EQ-5D will be used to evaluate quality of life of survivors
1-year mortality rate	All the participants will be followed up until 1 year after their enrollment or death	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026